Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-11-28 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2021年季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of a quarterly dividend distribution for the year 2021 by 圣湘生物科技股份有限公司. It details the dividend per share, relevant dates (record date, ex-dividend date, payment date), the approval of the dividend at a shareholders meeting, tax implications, and instructions for shareholders. The document length is 3081 characters, which is relatively short and typical for a dividend announcement. It does not contain financial statements or comprehensive financial data, but rather focuses on dividend distribution details. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2021-11-28 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司差异化分红事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution (西部证券股份有限公司) regarding a differentiated dividend distribution matter for 圣湘生物科技股份有限公司. It discusses the company's share repurchase plan, the impact on dividend distribution, and the calculation of ex-dividend prices. The document is a formal opinion or verification report related to a specific dividend distribution event, not the dividend announcement itself or a full financial report. It does not contain comprehensive financial statements or quarterly/yearly results but focuses on legal and regulatory compliance of the dividend distribution. This fits best under Regulatory Filings (RNS) as it is a compliance-related verification opinion rather than a full report or announcement of dividend amount.
2021-11-28 Chinese
圣湘生物科技股份有限公司关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares under a stock incentive plan by the company's board. It details the grant date, number of shares, recipients, approval process, legal and financial advisor opinions, and compliance with regulatory requirements. It is not a financial report, earnings release, or management discussion, but rather a formal disclosure about a capital-related event involving share grants to employees and executives. This fits the category of Capital/Financing Update (CAP), as it concerns changes in the company's capital structure through stock incentives. The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2021-11-23 Chinese
上海信公轶禾企业管理咨询有限公司关于圣湘生物科技股份有限公司2021年限制性股票激励计划首次授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a 2021 restricted stock incentive plan for a company. It contains detailed sections about the stock incentive plan, including definitions, assumptions, plan content, grant conditions, pricing, and performance targets. The document is a comprehensive advisory report prepared by an independent financial consultant regarding the stock incentive plan, which is a form of equity compensation. It is not an announcement of voting results, a proxy statement, or a regulatory filing. It is also not a general annual or quarterly financial report, nor an earnings release. The content focuses on the stock incentive plan and the independent financial advisor's opinions and analysis. This type of document fits best under the category of "Capital/Financing Update (CAP)" because it relates to equity incentives and capital structure changes through stock grants. The document length is substantial (15,000 characters), and it contains detailed substantive content, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2021-11-23 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2021年限制性股票激励计划授予相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 restricted stock incentive plan of a company. It discusses the approval, authorization, grant conditions, and compliance with relevant laws and regulations related to the stock incentive plan. There are no financial statements, earnings data, or management discussion of financial results. The document is not an announcement of a report but a legal opinion supporting a corporate action related to stock incentives. This type of document does not fit into financial reports, earnings releases, or management reports. It is a specialized legal opinion related to corporate governance and compliance with stock incentive regulations. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2021-11-23 Chinese
圣湘生物科技股份有限公司独立董事关于第一届董事会2021年第十次临时会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a specific board meeting matter related to a restricted stock incentive plan. It discusses the legality, compliance, and approval of the stock incentive plan and the granting of restricted shares. The document is short (1020 characters) and focuses on governance and compliance opinions rather than financial results or detailed financial data. It is not an annual report, earnings release, or financial supplement. It is not a regulatory filing or certification letter but a formal opinion related to board matters. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters such as stock incentive plans.
2021-11-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.